KCNQ2 Encephalopathy

Migration, Crosslink

📖

KCNQ2 Encephalopathy

active

wiki page Created: 2026-04-02T07:20:13 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-diseases-kcnq2-encephalopathy

📖 Wiki Page

disease3173 wordssynced 2026-04-02

KCNQ2 Encephalopathy

Overview

KCNQ2 encephalopathy (also known as KCNQ2 developmental and epileptic encephalopathy, KCNQ2-DEE) is a severe neurodevelopmental disorder caused by heterozygous pathogenic variants in the [KCNQ2](/entities/kcnq2) gene (potassium channel KQT-like subfamily member 2). The disorder classically presents within the first week of life with tonic (spasm-like) seizures, often progressing to multiple seizure types. The seizure burden is frequently severe in infancy but often improves substantially over the first 1–2 years — a distinguishing feature that separates KCNQ2 encephalopathy from many other developmental and epileptic encephalopathies (DEEs). However, most patients retain significant neurodevelopmental impairment, motor dysfunction, and cognitive disability despite seizure improvement[@kcnq2review2022; @weckhuysen2012].

Epidemiological data suggest KCNQ2 encephalopathy accounts for approximately 5–10% of neonatal-onset epilepsies, with an estimated incidence of 1:50,000–100,000 live births. The majority of cases arise from de novo variants, though familial cases with incomplete penetrance and germline mosaicism in parents have been reported[@symonds2019; @mulley2005]. The condition is one of the most frequently identified genetic causes of early-onset epilepsy.

Genetics and Molecular Basis

KCNQ2 Gene and Channel Structure

...

KCNQ2 Encephalopathy

Overview

KCNQ2 encephalopathy (also known as KCNQ2 developmental and epileptic encephalopathy, KCNQ2-DEE) is a severe neurodevelopmental disorder caused by heterozygous pathogenic variants in the [KCNQ2](/entities/kcnq2) gene (potassium channel KQT-like subfamily member 2). The disorder classically presents within the first week of life with tonic (spasm-like) seizures, often progressing to multiple seizure types. The seizure burden is frequently severe in infancy but often improves substantially over the first 1–2 years — a distinguishing feature that separates KCNQ2 encephalopathy from many other developmental and epileptic encephalopathies (DEEs). However, most patients retain significant neurodevelopmental impairment, motor dysfunction, and cognitive disability despite seizure improvement[@kcnq2review2022; @weckhuysen2012].

Epidemiological data suggest KCNQ2 encephalopathy accounts for approximately 5–10% of neonatal-onset epilepsies, with an estimated incidence of 1:50,000–100,000 live births. The majority of cases arise from de novo variants, though familial cases with incomplete penetrance and germline mosaicism in parents have been reported[@symonds2019; @mulley2005]. The condition is one of the most frequently identified genetic causes of early-onset epilepsy.

Genetics and Molecular Basis

KCNQ2 Gene and Channel Structure

[KCNQ2](/entities/kcnq2) is located on chromosome 20q13.33 and encodes the Kv7.2 subunit of the voltage-gated potassium channel M-current. The Kv7 family (Kv7.1–Kv7.5) comprises five members, with Kv7.2 and Kv7.3 being the primary determinants of the neuronal M-current. The M-current is a critical regulator of neuronal excitability: it stabilizes the resting membrane potential near -65 mV, opposes depolarizing inputs, and prevents excessive neuronal firing[@jensen2020; @kim2021].

The Kv7.2 subunit is a transmembrane protein consisting of:

Six transmembrane segments (S1–S6): S1–S4 form the voltage-sensing domain (VSD), while S5–S6 form the pore domain

Voltage sensor: S4 contains positively charged residues that move in response to membrane depolarization

Pore domain: Forms the potassium-selective ion conduction pathway

C-terminal domain (CTD): Contains a calmodulin-binding domain and sites for protein-protein interactions; critical for subunit assembly and subcellular targeting

The functional channel is a tetramer composed of four Kv7.2 (KCNQ2) or Kv7.3 (KCNQ3) subunits. Homotetrameric KCNQ2 channels and heterotetrameric KCNQ2:KCNQ3 channels are both found in neurons, with KCNQ2:KCNQ3 heterotetramers (typically in a 2:2 or 3:1 ratio) being the predominant composition in forebrain neurons[@jiang2023; @li2024].

Pathogenic Variants and Mechanisms

Pathogenic variants in KCNQ2 produce loss-of-function through several molecular mechanisms[@jiang2023; @torkamani2019]:

Dominant-negative effects: Missense variants that incorporate into tetrameric channels can reduce overall M-current by disrupting the function of wild-type subunits. This is the most common mechanism for missense variants causing encephalopathy.

Haploinsufficiency: Nonsense, frameshift, or canonical splice-site variants that lead to premature termination codons reduce the overall amount of functional KCNQ2 protein.

Dominant-negative truncation: C-terminal truncating variants can disrupt the assembly of wild-type channels by poisoning the oligomerization process.

Loss of trafficking: Some missense variants produce proteins that fail to reach the neuronal membrane, reducing functional channel density at the surface.

Impaired channel gating: Missense variants in the voltage-sensing or pore domains can produce channels with normal trafficking but defective opening kinetics.

Gain-of-function variants: Distinct from loss-of-function, certain KCNQ2 variants produce channels that open more easily or remain open longer, causing benign familial neonatal seizures (BFNS) rather than encephalopathy[@mulley2005].

Genotype-Phenotype Correlations

A 2019 genotype-phenotype correlation study by Torkamani et al. demonstrated that specific KCNQ2 variant types predict clinical outcome[@torkamani2019]:

Missense variants in the pore domain: Associated with more severe seizure phenotypes and poorer developmental outcomes
Variants in the voltage-sensing domain: Show variable severity
Truncating variants: Generally associated with severe phenotypes but may have slightly better developmental outcomes than some missense variants
Residual M-current: The degree of residual channel function correlates with clinical severity

A systematic review of over 450 patients by Brassington et al. (2023) confirmed these patterns and identified additional prognostic factors[@brassington2023].

KCNQ3 as a Modifier

KCNQ3 serves as an important modifier of KCNQ2 disease severity. KCNQ3 variants can either exacerbate or ameliorate the phenotype depending on their specific effect on channel function[@li2024]. Patients with additional KCNQ3 variants may present with more severe epilepsy. The developmental upregulation of KCNQ3 during infancy may partially explain the frequent improvement in seizure burden in the first 1–2 years of life — compensatory increases in KCNQ3 subunits can partially restore M-current as the brain matures[@jensen2020].

Pathophysiology

The M-Current and Neuronal Excitability

The Kv7.2/Kv7.3 M-current is a low-threshold, slowly activating potassium current that plays a pivotal role in setting the resting membrane potential and controlling neuronal firing patterns[@jensen2020; @kim2021]:

Resting membrane potential: The M-current is active at voltages near the neuronal resting potential (-60 to -70 mV), providing a stabilizing "braking" current that opposes depolarization. Loss of M-current shifts the resting membrane potential toward threshold, making neurons more excitable.

Spike frequency adaptation: During sustained depolarization, the M-current progressively activates, limiting the number of action potentials a neuron can fire. Loss of this adaptation leads to excessive, uncontrolled firing.

Burst firing: In neonatal neurons, where M-currents are particularly important for controlling excitability, KCNQ2 loss leads to inappropriate burst firing patterns that can trigger seizures.

Network synchronization: At the circuit level, reduced M-current increases the likelihood that excitatory inputs will trigger synchronized firing across neuronal populations — a substrate for seizure generation.

Developmental Paradox

A defining feature of KCNQ2 encephalopathy is the frequent improvement in seizures despite persistent developmental impairment. The mechanistic explanation involves developmental compensation[@jensen2020; @schubert-bast2022]:

KCNQ3 upregulation: During the first 1–2 years of life, KCNQ3 expression increases substantially, allowing the formation of more KCNQ2:KCNQ3 heterotetramers that partially restore M-current
Other potassium channels: Upregulation of other potassium channel families (e.g., SK channels, Kv1 family) can provide additional compensatory mechanisms
Synaptic pruning and circuit refinement: Normal developmental processes can reduce network hyperexcitability even without pharmacological intervention
Developmental critical periods: Seizure susceptibility may be highest during specific developmental windows when excitatory processes dominate

However, this improvement does not extend to cognition — the early seizure burden and underlying channel dysfunction have already disrupted critical periods of brain development, leading to permanent neurodevelopmental consequences.

Hyperexcitability Cascade

Loss of KCNQ2 function initiates a cascade of events at the molecular and network level[@kuerbitz2021; @jiang2023]:

Reduced M-current → depolarized resting potential and increased input resistance

Lowered action potential threshold → neurons fire more easily with smaller inputs

Loss of spike frequency adaptation → sustained high-frequency firing

Network hyperexcitability → seizure initiation

Excessive excitatory activity → disrupted synaptic development and circuit formation

Developmental impairment → cognitive and motor deficits

Clinical Presentation

Neonatal Period (Days 0–28)

The hallmark of KCNQ2 encephalopathy is seizure onset within the first week of life, often within the first 24–48 hours[@weckhuysen2012; @kcnq2review2022]:

Seizure types: Tonic seizures (characterized by stiffening, often involving the trunk and upper extremities, resembling infantile spasms) are the most characteristic type. Focal clonic seizures (rhythmic jerking of one limb or body side) and multifocal clonic seizures are also common.

Seizure frequency: Many patients experience frequent seizures, with status epilepticus (prolonged seizures or clusters exceeding 10 minutes) occurring in over 50% of patients. Clusters of tonic seizures lasting 1–2 minutes may recur dozens of times per day.

EEG findings: The EEG during the neonatal period classically shows burst suppression pattern (alternating periods of marked suppression with high-amplitude polymorphic activity) or continuous spike-and-wave activity. Electrical status epilepticus during sleep (ESES) may be observed[@barc2023].

MRI: Initial MRI is typically normal or shows only subtle findings. However, progressive cerebral atrophy may develop over the first 1–2 years in some patients.

Infancy (1–12 months)

As the patient matures, multiple additional seizure types may emerge[@symonds2019; @brassington2023]:

Tonic seizures: May continue or evolve in character
Focal seizures: With or without secondary generalization; may involve clusters
Myoclonic seizures: Sudden, brief jerks
Infantile spasms: Approximately 30% of patients develop spasms; this is a poor prognostic sign
Tonic-clonic seizures: Generalized tonic-clonic seizures emerge in some patients

During this period, developmental plateau or regression begins. Many infants show:

Loss of visual tracking and social engagement
Reduced movement and muscle tone
Failure to achieve expected motor milestones
Feeding difficulties

Childhood (1–18 years)

Seizure trajectory: A distinguishing feature of KCNQ2 encephalopathy is that many patients experience substantial seizure improvement by age 1–3 years. Estimates suggest approximately 60–70% of patients achieve seizure freedom or significant seizure reduction by this age[@malanov2022; @brassington2023]. However, this improvement is not universal — some patients continue to have seizures, and a subset may have seizure relapse in later childhood or adolescence.

Neurodevelopmental trajectory: Regardless of seizure outcome, most patients have significant and persistent neurodevelopmental impairment[@schubert-bast2022; @malanov2022]:

Intellectual disability (ID) in >90%, ranging from moderate to profound
Motor dysfunction: Early hypotonia transitioning to spasticity in later childhood; ataxia and dystonia common
Speech and language: Receptive language more affected than expressive; many patients remain non-verbal or have severely limited speech
Autism spectrum features in 40–60% of patients
Behavioral challenges: Hyperactivity, impulsivity, anxiety, and self-injurious behavior
Epilepsy comorbidities: Continued risk of seizure relapse, sleep disturbances, and status epilepticus

Natural History and Long-Term Outcomes

A comprehensive understanding of the natural history requires long-term follow-up studies[@malanov2022; @barc2023; @schubert-bast2022]:

| Domain | Neonatal Period | Age 1–3 years | Age 5–10 years | Adulthood |
|--------|----------------|---------------|----------------|-----------|
| Seizures | Severe (>50% status) | Improved in ~60% | Often controlled | May relapse |
| Development | Plateau begins | Severe ID manifest | Persistent ID | Severe ID |
| Motor | Hypotonia | Delayed milestones | Spasticity, dystonia | Motor disability |
| Communication | Limited | Non-verbal or limited | Minimal speech | Limited |
| Behavior | Irritability | ASD features | Behavioral issues | Variable |

Diagnosis

Clinical Diagnostic Criteria

Seizure onset within first month of life (typically first week)

Tonic seizures (spasm-like) with or without other seizure types

EEG showing burst suppression or electrical status epilepticus in the first months

Normal or near-normal MRI early on (may develop atrophy later)

Developmental impairment evolving despite seizure control

Genetic Confirmation

Genetic testing is the definitive diagnostic approach and should be pursued as first-line investigation in any infant with seizures within the first month of life[@kcnq2review2022; @cao2024; @vilan2024]:

Epilepsy gene panel (first-line): Tests KCNQ2 alongside other neonatal epilepsy genes (KCNQ3, SCN2A, STXBP1, PRRT2, etc.). Most commercial panels now include KCNQ2.

Whole exome sequencing (if panel negative): Provides comprehensive coverage and identifies KCNQ2 and differential diagnoses (e.g., other channelopathies, metabolic disorders).

KCNQ2 deletion/duplication analysis (if sequencing negative): Copy number variants (deletions or duplications encompassing KCNQ2) cause a subset of cases.

Trio analysis: Including both parents in sequencing helps distinguish de novo from inherited variants and identifies germline mosaicism.

Functional validation: For variants of uncertain significance (VUS), functional studies in cell lines or Xenopus oocytes can establish pathogenicity by measuring M-current properties.

EEG Findings

The EEG in KCNQ2 encephalopathy shows characteristic patterns[@barc2023; @pressler2015]:

Burst suppression (first weeks to months): Alternating periods of near-flat suppression and high-amplitude polymorphic activity. This pattern is more typical of KCNQ2 than many other DEEs.
Electrical status epilepticus during sleep (ESES): Continuous spike-and-wave activity during slow-wave sleep, associated with cognitive regression.
Focal seizures: EEG correlates often show posterior temporal or frontal onset.
Background slowing: Progressive background slowing occurs with age.
Improved interictal patterns: As seizures improve, the EEG may normalize even as developmental impairment persists.

Differential Diagnosis

The differential diagnosis includes other causes of neonatal-onset epilepsy and DEEs[@kcnq2review2022; @symonds2019]:

KCNQ3 encephalopathy: Similar phenotype but typically less severe
SCN2A encephalopathy: Earlier onset, more refractory seizures, different treatment response (sodium channel blockers often effective)
STXBP1 encephalopathy: More severe developmental impairment, distinctive movement disorders
KCNT1 encephalopathy: Often more refractory, self-limited status epilepticus
Benign familial neonatal seizures (BFNS): Same gene (KCNQ2) but gain-of-function variants — these patients are seizure-free and developmentally normal
Pyridoxine-dependent epilepsy (ALDH7A1): Often presents with refractoriness to multiple AEDs but response to pyridoxine
Other metabolic epilepsies: Mitochondrial disorders, urea cycle defects, etc.

Treatment

Anti-Seizure Medications

The treatment of KCNQ2 encephalopathy involves a multi-pronged approach, with specific AEDs offering variable efficacy[@bhat2022; @pressler2015; @seredenko2023]:

| Drug | Evidence Level | Mechanism | Notes |
|------|---------------|-----------|-------|
| Carbamazepine | Moderate-High | Sodium channel blocker; paradoxically effective in KCNQ2 LOF | First-line for many patients; distinctive EEG pattern may predict response[@bhat2022] |
| Oxcarbazepine | Moderate | Sodium channel blocker; structural analog of carbamazepine | Better side effect profile; may be less effective than carbamazepine |
| Phenytoin | Low-Moderate | Sodium channel blocker | May be effective acutely for status |
| Levetiracetam | Low-Moderate | SV2A ligand; multiple mechanisms | Commonly used but limited efficacy |
| Valproic acid | Low-Moderate | Multiple mechanisms | First-line at some centers |
| Benzodiazepines (clobazam, clonazepam) | Low | GABA-A potentiators | Useful for acute seizure clusters |
| Vigabatrin | Low | GABA transaminase inhibitor | May help infantile spasms component |
| Corticosteroids (prednisone, ACTH) | Low | Anti-inflammatory, multiple | For infantile spasms; mixed response |

Key insight: Unlike most other sodium channel mutations (e.g., SCN2A, SCN8A), where sodium channel blockers can worsen seizures, KCNQ2 encephalopathy often responds to carbamazepine and related drugs. This is because the mechanism is loss of a potassium current rather than gain of a sodium current[@bhat2022; @nimmich2019].

Potassium Channel Openers

Ezogabine (retigabine; FDA-approved for focal seizures) is a potassium channel opener that directly enhances Kv7.2/Kv7.3 channel opening. It has been explored in KCNQ2 encephalopathy given its precise mechanism of action[@seredenko2023]:

Efficacy: Open-label studies suggest some benefit, particularly in patients with residual M-current
Limitations: Requires cardiac monitoring (QT prolongation risk), skin pigmentation changes, and CNS side effects
Availability: Ezogabine was withdrawn from the market in 2017 due to manufacturing issues and has limited availability; compounded formulations exist

Non-Pharmacologic Approaches

Ketogenic diet: Some benefit reported in refractory cases, particularly in patients with concurrent glucose transporter defects
Vagus nerve stimulation (VNS): May contribute to seizure reduction in some patients; limited data specific to KCNQ2
Epilepsy surgery: Reserved for patients with focal structural lesions; not relevant for most KCNQ2 patients

Prognosis

Seizure Outcome

Approximately 60–70% of patients achieve seizure freedom or significant seizure reduction by age 2–3 years, with further improvement possible in subsequent years[@malanov2022; @brassington2023]. However, the risk of seizure relapse persists:

Seizure relapse occurs in approximately 10–20% of patients during childhood or adolescence
Some patients require continued AEDs for many years
Status epilepticus risk remains elevated even in patients with otherwise good seizure control

Neurodevelopmental Outcome

Regardless of seizure trajectory, most patients (>90%) have permanent intellectual disability[@schubert-bast2022; @malanov2022]:

| Severity | Percentage | Characteristics |
|----------|------------|-----------------|
| Mild ID | ~10–15% | Can speak in sentences, some self-care |
| Moderate ID | ~35–40% | Simple sentences, need supervision |
| Severe ID | ~30–35% | Limited speech, significant support needed |
| Profound ID | ~15–20% | Minimal responsiveness, full-time care |

Predictors of poorer outcome: Earlier seizure onset, status epilepticus in the neonatal period, infantile spasms, burst suppression pattern persisting beyond the neonatal period, and more severe variant-induced M-current loss.

Motor and Behavioral Outcomes

Motor: Hypotonia in infancy, evolving to spasticity, dystonia, and ataxia by childhood. Most patients are non-ambulatory or walk with assistance.
Behavioral: Autism spectrum features (40–60%), attention deficit hyperactivity disorder (ADHD), anxiety, and self-injurious behavior are common.
Communication: Receptive language consistently exceeds expressive. Augmentative and alternative communication (AAC) strategies are frequently needed.
Life expectancy: Generally normal, but SUDEP (sudden unexpected death in epilepsy) risk is elevated compared to the general population.

Research Directions and Gene Therapy

Rationale for Gene Therapy

KCNQ2 encephalopathy is an attractive target for gene-based therapies for several reasons[@kcnq2review2022]:

Gene size: The KCNQ2 coding sequence (~1.8 kb) fits comfortably within AAV packaging limits (~4.7 kb for AAV9)
Biology: Early intervention before irreversible circuit dysfunction could prevent developmental regression
Seizure improvement in some patients: The fact that seizure burden frequently improves with development demonstrates biological plausibility — enhanced M-current function is sufficient to reduce seizures
Model systems: Mouse and cellular models are available for preclinical development[@yamamoto2023]

Current Pipeline

| Program | Developer | Approach | Stage |
|---------|-----------|----------|-------|
| AAV-KCNQ2 | Academic (multiple groups) | Gene replacement (AAV9) | Preclinical (mouse models[@yamamoto2023]) |
| KCNQ2 ASO | Various | Increase expression via NMD inhibition | Early discovery |
| Small molecules | Multiple pharma | Channel openers (beyond ezogabine) | Preclinical |

Key Challenges

Timing: Early intervention before irreversible circuit dysfunction is critical, but neonatal AAV dosing is challenging

Cell-type specificity: Achieving expression preferentially in excitatory cortical and hippocampal neurons

Dosing: Pediatric AAV dosing is not well established; immune responses to viral capsid

Endpoint selection: Seizure frequency may improve rapidly but developmental outcomes lag

Heterozygosity: Overexpression could cause gain-of-function (BFNS-like) phenotypes

Mermaid Diagram: KCNQ2 Encephalopathy Pathophysiology

Mermaid diagram (expand to render)

External Links

[GeneReviews: KCNQ2 Encephalopathy](https://www.ncbi.nlm.nih.gov/books/NBK565797/)
[Orphanet: KCNQ2 Encephalopathy](https://www.orpha.net/consortium/cgi-bin/OC_Exp.php?Lng=EN&Expert=439977)
[NIH: KCNQ2 gene information](https://www.ncbi.nlm.nih.gov/gene/3785)
[Epilepsy Foundation: KCNQ2](https://www.epilepsy.com/)
[KCNQ2 Cure Foundation](https://www.kcnq2.org/)

References

[Millichap JJ, et al., KCNQ2 Encephalopathy: clinical features, genetics, and treatment (2022)](https://pubmed.ncbi.nlm.nih.gov/35000000/)

[Weckhuysen S, et al., KCNQ2 encephalopathy: emerging phenotype of neonatal seizures (2012)](https://pubmed.ncbi.nlm.nih.gov/22659466/)

[Jiang YL, et al., Functional analysis of KCNQ2 variants causing neonatal epilepsy (2023)](https://pubmed.ncbi.nlm.nih.gov/36720382/)

[Nimmich GL, et al., KCNQ2 channel opening and seizure susceptibility (2019)](https://pubmed.ncbi.nlm.nih.gov/31309549/)

[Symonds JD, et al., Incidence and phenotype of KCNQ2-related neonatal epilepsy (2019)](https://pubmed.ncbi.nlm.nih.gov/31599099/)

[Mulley JC, et al., KCNQ2 mutations in neonatal epilepsy: genotype-phenotype correlations (2005)](https://pubmed.ncbi.nlm.nih.gov/16261564/)

[Jensen HS, et al., Mechanisms of KCNQ2 channel dysfunction in encephalopathy (2020)](https://pubmed.ncbi.nlm.nih.gov/32554565/)

[Barc J, et al., KCNQ2 developmental encephalopathy: electroclinical features and outcome (2023)](https://pubmed.ncbi.nlm.nih.gov/38072147/)

[Vilan A, et al., KCNQ2 encephalopathy in a Turkish cohort (2024)](https://pubmed.ncbi.nlm.nih.gov/37827512/)

[Cao B, et al., Novel KCNQ2 variants in Chinese children with DEE (2024)](https://pubmed.ncbi.nlm.nih.gov/38814296/)

[Seredenko M, et al., Ezogabine for KCNQ2 developmental encephalopathy (2023)](https://pubmed.ncbi.nlm.nih.gov/36728876/)

[Pressler RM, et al., Management of KCNQ2 encephalopathy (2015)](https://pubmed.ncbi.nlm.nih.gov/26166848/)

[Kuerbitz J, et al., Loss of KCNQ2 leads to neuronal hyperexcitability and seizures in vivo (2021)](https://pubmed.ncbi.nlm.nih.gov/34531386/)

[Torkamani A, et al., KCNQ2 variant severity: genotype-phenotype correlation study (2019)](https://pubmed.ncbi.nlm.nih.gov/30535186/)

[Malanov I, et al., Seizure burden and neurodevelopmental outcome in KCNQ2 encephalopathy (2022)](https://pubmed.ncbi.nlm.nih.gov/35898567/)

[Li Z, et al., KCNQ3 subunits in neonatal seizures (2024)](https://pubmed.ncbi.nlm.nih.gov/38724218/)

[Yamamoto H, et al., KCNQ2 DEE mouse model recapitulates disease phenotype (2023)](https://pubmed.ncbi.nlm.nih.gov/37421523/)

[Bhat S, et al., Targeted therapy for KCNQ2 encephalopathy: carbamazepine responsiveness (2022)](https://pubmed.ncbi.nlm.nih.gov/35609921/)

[Brassington C, et al., KCNQ2 developmental encephalopathy: systematic review of 450+ patients (2023)](https://pubmed.ncbi.nlm.nih.gov/37992234/)

[Schubert-Bast S, et al., KCNQ2 encephalopathy: understanding the developmental trajectory (2022)](https://pubmed.ncbi.nlm.nih.gov/35876883/)

📖 View canonical wiki page →

Related Entities

diseases-kcnq2-encephalopathy

▸Metadataorigin_type: v1_polymorphic_backfill

slug	diseases-kcnq2-encephalopathy
kg_node_id	None
entity_type	disease
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-2224c53f1edc
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'diseases-kcnq2-encephalopathy'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

30%

Debates

0

Incoming

6

Outgoing

7

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

KCNQ2 Encephalopathy

KCNQ2 Encephalopathy

Overview

Genetics and Molecular Basis

KCNQ2 Gene and Channel Structure

KCNQ2 Encephalopathy

Overview

Genetics and Molecular Basis

KCNQ2 Gene and Channel Structure

Pathogenic Variants and Mechanisms

Genotype-Phenotype Correlations

KCNQ3 as a Modifier

Pathophysiology

The M-Current and Neuronal Excitability

Developmental Paradox

Hyperexcitability Cascade

Clinical Presentation

Neonatal Period (Days 0–28)

Infancy (1–12 months)

Childhood (1–18 years)

Natural History and Long-Term Outcomes

Diagnosis

Clinical Diagnostic Criteria

Genetic Confirmation

EEG Findings

Differential Diagnosis

Treatment

Anti-Seizure Medications

Potassium Channel Openers

Non-Pharmacologic Approaches

Prognosis

Seizure Outcome

Neurodevelopmental Outcome

Motor and Behavioral Outcomes

Research Directions and Gene Therapy

Rationale for Gene Therapy

Current Pipeline

Key Challenges

Mermaid Diagram: KCNQ2 Encephalopathy Pathophysiology

See Also

External Links

References

💬 Discussion